GSK plc (NYSE:GSK) Shares Sold by Royal Fund Management LLC

Royal Fund Management LLC decreased its holdings in GSK plc (NYSE:GSK) by 43.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 24,025 shares of the pharmaceutical company’s stock after selling 18,431 shares during the period. Royal Fund Management LLC’s holdings in GSK were worth $813,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also modified their holdings of the stock. Eastern Bank acquired a new position in GSK during the 3rd quarter worth $26,000. ST Germain D J Co. Inc. grew its position in shares of GSK by 195.5% during the fourth quarter. ST Germain D J Co. Inc. now owns 789 shares of the pharmaceutical company’s stock worth $27,000 after buying an additional 522 shares in the last quarter. Sunbelt Securities Inc. increased its stake in shares of GSK by 73.8% during the third quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company’s stock worth $29,000 after buying an additional 302 shares during the period. Concord Wealth Partners raised its holdings in GSK by 231.8% in the third quarter. Concord Wealth Partners now owns 783 shares of the pharmaceutical company’s stock valued at $32,000 after acquiring an additional 547 shares in the last quarter. Finally, Fortitude Family Office LLC purchased a new position in GSK in the third quarter worth approximately $42,000. Hedge funds and other institutional investors own 15.74% of the company’s stock.

Analyst Ratings Changes

GSK has been the topic of a number of analyst reports. Deutsche Bank Aktiengesellschaft lowered shares of GSK from a “buy” rating to a “hold” rating in a report on Friday, November 15th. Guggenheim cut GSK from a “buy” rating to a “neutral” rating in a research note on Thursday, October 31st. StockNews.com cut GSK from a “strong-buy” rating to a “buy” rating in a research report on Tuesday. Finally, Jefferies Financial Group cut GSK from a “buy” rating to a “hold” rating and decreased their target price for the stock from $53.00 to $39.50 in a research note on Tuesday, November 12th. Seven investment analysts have rated the stock with a hold rating, one has given a buy rating and three have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $43.25.

GSK Trading Up 1.0 %

Shares of GSK stock opened at $33.76 on Wednesday. The company has a market capitalization of $69.98 billion, a P/E ratio of 21.92, a PEG ratio of 1.45 and a beta of 0.63. GSK plc has a 1 year low of $31.72 and a 1 year high of $45.92. The company’s fifty day moving average is $33.96 and its two-hundred day moving average is $37.94. The company has a debt-to-equity ratio of 0.98, a quick ratio of 0.53 and a current ratio of 0.81.

GSK Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, January 9th. Investors of record on Friday, November 15th were issued a dividend of $0.3928 per share. The ex-dividend date was Friday, November 15th. This is an increase from GSK’s previous quarterly dividend of $0.38. This represents a $1.57 annualized dividend and a dividend yield of 4.65%. GSK’s dividend payout ratio (DPR) is currently 95.45%.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.